C-reactive protein: A useful tool for evaluation of clinical activity in Crohn's disease?

C-Reactive Protein: New Research

Volumn , Issue , 2009, Pages 43-49

  Karoui, Sami ^a   Serghini, Meriem ^a   Boubaker, Jalel ^a   Filali, Azza ^a  

^a LA RABTA HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959688970     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (25)

1. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A (2003). Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 17 (Suppl 2):11-17.
2. Loftus EV Jr (2007). Objectives measures of disease activity: Alternatives to symptom indices. Rev Gastroenterol Disord 7(Suppl2): S8-S16.
3. Sands BE, Jin Ooi C (2005). A survey of methodological variation in the Crohn's Disease Activity Index. Inflamm Bowel Dis 11:133-138.
4. Monteleone G, Fina D, Caruso R, Pallone F (2006). New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 22:361-364.
5. Tall AR (2004). C-reactive protein reassessed. N Engl J Med 350:1450-1452.
6. Vermeire S, Van Assche G, Rutgeerts P (2004). C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10:661-665.
7. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Fiasse R et al (2002). A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 17:818-824.
8. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, Pepys MB (1982). Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 12:351-359.
9. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F (1988). The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10:401-405.
10. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R (1994). Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 35:231-235.
11. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ (2005). Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11:707-712.
12. Filik L, Dagli U, Ulker A (2006). C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther 23:655-62.
13. Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R (2006). Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 4:882-887.
14. Karoui S, Ouerdiane S, Serghini M, Jomni T, Kallel L, Fekih M, Boubaker J, Filali A (2007). Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis 39:1006-1010.
15. Rodgers AD, Cummins AG (2007). CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 52:2063-2068.
16. Mary JY, Modigliani R (1989). Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du tube Digestif (GETAID). Gut 30:983-989.
17. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2008). Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40-46.
18. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ (2008). Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103:162-169
19. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG (2006). Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 55:1561-1567.
20. Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R (2007). Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 48:1053-1059.
21. Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B (2008). Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci. 53:242-7.
22. Irving PM, Gibson PR (2008). Infections and IBD. Nature Clin Pract Gastroenterol Hepatol 5:18-27.
23. Thalmaier D, Dambacher J, Seiderer J, Konrad A, Schachinger V, Pfennig S, Otte JM, Crispin A, Göke B, Ochsenkühn T, Lohse P, Brand S (2006). The +1059G/C polymorphism in the C-reactive protein gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmcol Ther 24:1105-1115.
24. Florin THJ, Paterson EWJ, Fowler EV, Radford-Smith GL (2006). Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 41:306-311.
25. Denis MA, Reenaers C, Fontaine F, Belaïche J, Louis E (2007). Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 13:1100-1105.